IL1RL2 and psoriasis 14, pustular: Increased lesional IL-36γ levels have also been described (Johnston et al., 2017) and a blocking anti-IL36R antibody has been recently approved for the treatment of generalized pustular psoriasis (Bachelez et al., 2021; Elewski et al., 2023).